Furthermore, future clinical studies should evaluate whether the ratio of CXCR3-A to CXCR3-B expression on circulating immune cells and tumor cells, combined with serum CXCL10 levels, serves as a more precise prognostic indicator of metastatic susceptibility. This evidence concerns the gene CXCR3 and neoplasm.